T-cell reactivity and α-synuclein in early and prodromal Parkinson’s disease
Parkinson's disease is characterized by the aggregation of the protein α-synuclein, primarily in dopaminergic neurons. Inflammatory processes may considerably contribute to disease development and progression. The underlying cellular and molecular mechanisms remain poorly investigated. By using human samples, the scientists are investigating the role of a specific subset of immune cells, namely T-cells, in various disease stages.
RESPONSE RSV – Investigation of the immune RESPonse after vaccination against RSV infection in immunocompromised patients with haematoONcological diseaSEs
The Respiratory Syncytial Virus (RSV) causes severe respiratory illnesses, particularly in children under the age of two years, elderly, and immunocompromised individuals, such as those with haematological diseases. Although RSV vaccines have recently been approved, data on their efficacy in this high-risk group are still lacking. The aim of this study is to examine the immune response to RSV vaccination in patients with haematological conditions over 12 months. Both, the humoral (antibody) and cellular immune responses will be analysed.
Impact of gut microbiota and microbiota-derived metabolites in severe acute pancreatitis – a global prospective clinical-translational study
Acute pancreatitis (AP) is a common and potentially life-threatening disease without causative therapeutic options. The composition of the gut microbiome could play a decisive pathophysiological role since AP significantly disrupts the intestinal barrier, triggering a life-threatening inflammatory response syndrome.
ForTra: EUR 4 million for GMP production of clinical study material for gene and cell therapies
ForTra is announcing a call for proposals to produce cell and gene therapeutics under Good Manufacturing Practice (GMP) conditions which are intended to be subsequently utilized in a clinical study involving patients.
Gene and cell therapies are developing rapidly and are key to future medical treatment strategies. This is being addressed, among other things, by the funding measures of the National Strategy for Gene and Cell-Based Therapies.